STOCK TITAN
  1. Home
  2. Sec-filings
  3. PAVM
  4. [Form 4] PAVmed Inc. Insider Trading Activity

PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aklog Lishan reported acquisition or exercise transactions in this Form 4 filing.

PAVmed Inc. Chairman and CEO Lishan Aklog received a grant of 350,000 shares of restricted common stock, awarded at $0.00 per share as equity compensation. The restricted stock was granted under PAVmed's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The award is subject to forfeiture if the required service period is not completed, tying the grant to long-term leadership retention. Following this grant, Dr. Aklog directly holds 357,614 shares of common stock, with additional indirect interests reported through family members and investment entities.

Positive

  • None.

Negative

  • None.
Insider Aklog Lishan
Role Chairman and CEO
Type Security Shares Price Value
Grant/Award Common Stock 350,000 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 357,614 shares (Direct); Common Stock — 5 shares (Indirect, By daughter)
Footnotes (1)
  1. Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein. Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
Restricted stock grant 350,000 shares Common stock awarded to CEO on 2026-04-02
Grant price $0.00 per share Price for restricted stock grant to CEO
Vesting date May 20, 2029 Single vesting date for restricted stock award
Direct holdings after grant 357,614 shares CEO direct PAVmed common stock following transaction
Indirect holdings via Pavilion Venture Partners LLC 9,904 shares PAVmed common stock held by Pavilion Venture Partners LLC
Indirect holdings via HCFP/AG LLC 45 shares PAVmed common stock held by HCFP/AG LLC
Indirect holdings by daughter 5 shares PAVmed common stock reported as held by daughter
Indirect holdings by son 5 shares PAVmed common stock reported as held by son
restricted stock financial
"Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan financial
"granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"
vesting date financial
"with a single vesting date of May 20, 2029"
dispositive power financial
"therefore has sole voting and dispositive power over the securities held by this entity"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
beneficial ownership financial
"disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aklog Lishan
(Last)(First)(Middle)
360 MADISON AVENUE, 25TH FLOOR
(Street)
NEW YORK NEW YORK 10017
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/02/2026A350,000(1)A$0357,614D
Common Stock5IBy daughter
Common Stock5IBy son
Common Stock9,904I(2)By Pavilion Venture Partners LLC
Common Stock45I(3)By HCFP/AG LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
2. Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and therefore has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
3. Dr. Aklog is a co-manager of HCFP/AG LLC, and therefore has joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
/s/ Michael A. Gordon, by power of attorney04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PAVmed (PAVM) report for CEO Lishan Aklog?

PAVmed reported that CEO Lishan Aklog received a grant of 350,000 shares of restricted common stock. The shares were awarded at $0.00 per share as equity compensation, increasing his direct holdings and aligning his interests with long-term company performance.

When do Lishan Aklog’s new PAVmed (PAVM) restricted shares vest?

The 350,000 restricted PAVmed shares granted to Lishan Aklog vest on May 20, 2029. This single vesting date requires him to remain in service through that point, or the restricted stock can be forfeited under the plan’s terms.

How many PAVmed (PAVM) shares does Lishan Aklog hold after this Form 4?

After the grant, Lishan Aklog directly holds 357,614 shares of PAVmed common stock. The filing also reports small indirect holdings through his daughter, son, Pavilion Venture Partners LLC, and HCFP/AG LLC, reflecting various ownership channels tied to him.

What conditions apply to Lishan Aklog’s new PAVmed (PAVM) restricted stock?

The restricted stock is subject to forfeiture if the required service period is not completed. All 350,000 shares vest on May 20, 2029, meaning continued service through that date is needed to fully secure the equity award.

What indirect PAVmed (PAVM) holdings linked to Lishan Aklog are disclosed?

The filing shows 5 PAVmed shares held by his daughter, 5 by his son, 9,904 by Pavilion Venture Partners LLC, and 45 by HCFP/AG LLC. Footnotes note his voting or dispositive power and disclaim beneficial ownership except for his pecuniary interest.